Fast Track Initiative

Bioqube Ventures is a specialist life sciences investment firm based in Europe and US with a global footprint. We source, finance and develop innovative therapeutic assets and technologies. We put our venture creation experience at work to translate and de-risk scientific innovation, advancing our investment portfolio and maximising value for investors. Bioqube Ventures is dedicated to funding therapeutic innovations: … a life sciences venture capital fund – dedicated to advancing exciting science in European and US ecosystems to breakthrough therapies for patients. … a fit-for-purpose dual investment model – besides more classical investments in investment rounds, we have special attention for venture creation projects that require additional experiments prior to creating new ventures. With our in-house factory model we are able to translate exciting science into trailblazing companies. … a hands-on approach – the team is a mix of fund managers, sector experts and serial entrepreneurs that have a proven track record in successfully leading companies on their growth paths. We believe in putting our expertise at work where it matters.

Cure Ventures harnesses its team's skills and decades of company-building experience to create innovative companies that aim to eradicate diseases by focusing on de novo company formation built around bold ideas and visionary entrepreneurs. Cure Ventures will provide the right level of human and financial capital that is required at each stage of the company's life. We seek to build great companies around pioneering scientific solutions with strong intellectual property positions. The Cure Ventures team intends to focus on disruptive technologies that target high unmet patient needs. The optimal company build will exhibit a clear genetic validation, substantiated and rigorously derived scientific data. the provenance of a distinguished scientific laboratory, biology with mechanistic clarity, multiple commercial applications, large uncrowded markets, expedited clinical routes, string partnering interest from large pharmaceutical companies, and an articulable oath to an exit.

When we founded the firm in 2007, our imaginations were on fire with the possibility of translating scientific discoveries to breakthrough medicines. Could we finally find cures for cancer? Would we be able to diagnose diseases before they even appear? How far could we go in restoring hope and quality of life to patients with incurable conditions? We dared to believe that nothing was impossible. To achieve what hadn’t been done before, we created a process that hadn’t been done before. By starting with big ideas and fostering collaboration among brilliant people with expertise in science, medicine, business and strategy, we set out to do more than fund startups – we aim to build sustainable, innovative companies that can transform the lives of patients. Discover Our Discovery effort is a collaborative and iterative process. We look for emerging fields of science and medicine where the time is right for us to bring transformative change to areas of unmet medical need. Working with leading scientific founders and expert advisors, we then develop a clear vision and strategy for a company with the patient front and center. With 12 years and over 50 companies worth of experience, we have created an industry-leading and differentiated approach to bring breakthrough science to patients. Launch Once a company concept has been refined and optimized through our Discovery process, we Launch the company with the necessary financial, technical and human resources to enable it to reach milestones critical for its growth and success. We become active members of the company’s leadership team, serving in interim roles to ensure the execution of the company’s R&D strategy, and to build a world-class team that shares the company’s scientific vision. Importantly, we work to establish a dynamic and innovative culture at launch where the growing team has a unified passion and commitment to make a difference in the lives of patients. Build Next, we Build on that foundation. We transition out of our interim roles and establish experienced and motivated management teams. As board members and domain experts, we work with these teams for as long as is needed to relentlessly execute on the strategy, bringing whatever resources are required from within the firm to deliver on our commitment to patients. An important element is the work we do to cultivate future partnerships and drive value creating transactions. Our companies also have access to our Beyond Great learning community, which provides peer-to-peer networking for leaders across the portfolio as well as tools and resources focused on shared elements of building successful and sustainable companies. Transform Our companies are now bringing products to patients – Transforming their lives, and the lives of their families. Third Rock portfolio companies have now launched 16 products. It is this that we are most proud of, as it means we are delivering on our mission of creating great companies that discover and develop products that make a difference for the patients we serve. Mission & Core Values Third Rock's mission is to be the preferred partner for entrepreneurs, investors, employees and industry to build great companies that discover and develop products that make a difference for the patients we serve. Integrity: always do the right thing Attitude: nothing is impossible Patients: making a difference through breakthroughs in medicine Partners: make them raving fans Organization: great people, great culture, great accomplishments Entrepreneurs: passionately innovate, found, build, have fun

Our deep resources and industry knowledge make us the ideal partner to scientists and entrepreneurs worldwide. Pivotal Life Sciences is an investment platform that specializes in providing capital to innovative companies developing therapeutic products and technologies to address major unmet medical needs. The name “Pivotal” synthesizes our investment approach with the role we strive to play in the companies we invest in. Our strategy is to invest in companies of all stages, with a primary focused on “high impact” therapeutics – solutions that address growing unmet medical needs and with near-curative or otherwise transformative disease management potential. We look for companies at the cusp of their greatest de-risking value inflection point and strive to play a key role in company building alongside management.

With a passion for advancing healthcare and a keen focus on fostering innovation, FHCV is dedicated to supporting companies developing new and transformative medicines, as well as investing in other venture capital funds operating in the life sciences sector. FHCV invests in companies that are pushing the boundaries of medical research and development, with a particular emphasis on those developing novel therapies. FHCV seeks out opportunities where breakthrough technologies and transformative ideas have the potential to address significant unmet medical needs and revolutionize patient care. The organization also invests in venture capital funds specializing in life sciences and seeks to leverage their expertise and network to access a diverse range of investment opportunities. This approach allows FHCV to diversify its portfolio while also benefiting from the specialized knowledge and due diligence capabilities of these investment partners.

We build breakthrough biotechnology companies. Exceptional entrepreneurs and scientists translate innovation into novel medicines. We play the long game with urgency. Patience, discipline, and vision to bring new transformational medicines to life. We are relentless truth-seekers. Our seed-led investment model uncovers the most promising opportunities. We understand the power of community. We prioritize a collaborative, science-first, patient-centric culture.